Search hospitals > California > Fremont

Center For Dermatology Cosmetic and Laser Surgery

Claim this profile
Fremont, California 94538
Conducts research for Atopic Dermatitis
Conducts research for Eczema
Conducts research for Psoriasis
Conducts research for Vitiligo
Conducts research for Acne
16 reported clinical trials
1 medical researcher
Photo of Center For Dermatology Cosmetic and Laser Surgery in FremontPhoto of Center For Dermatology Cosmetic and Laser Surgery in FremontPhoto of Center For Dermatology Cosmetic and Laser Surgery in Fremont

Summary

Center For Dermatology Cosmetic and Laser Surgery is a medical facility located in Fremont, California. This center is recognized for care of Atopic Dermatitis, Eczema, Psoriasis, Vitiligo, Acne and other specialties. Center For Dermatology Cosmetic and Laser Surgery is involved with conducting 16 clinical trials across 15 conditions. There are 1 research doctors associated with this hospital, such as Sunil Dhawan.

Top PIs

Clinical Trials running at Center For Dermatology Cosmetic and Laser Surgery

Atopic Dermatitis
Eczema
Hidradenitis Suppurativa
Oral Lichen Planus
Lichen Planus
Image of trial facility.

Amlitelimab + Topical Corticosteroids

for Atopic Dermatitis (AQUA)

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 [RIVER-AD]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 [RIVER-AD]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 [RIVER-AD] study).
Recruiting1 award Phase 35 criteria
Image of trial facility.

Amlitelimab

for Eczema

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD). The main objective of this study is to evaluate if those participants who received amlitelimab dose 1 in the parent studies (EFC17559 \[COAST-1\], EFC17560 \[COAST 2\], EFC17561 \[SHORE\]) and were responders can maintain their response either remaining at dose 1 or switching to dose 2 of amlitelimab compared to treatment withdrawal. Study details include: The study duration will be up to 64 weeks (for participants not entering the LTS17367 \[RIVER-AD\] study) including a 48-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 48 weeks for participants entering the LTS17367 \[RIVER-AD\] study at the Week 48 visit of EFC17600 (ESTUARY). The total treatment duration will be up to 48 weeks. The total number of visits will be up to 14 visits (or 13 visits for those entering LTS17367 \[RIVER-AD\] study).
Recruiting1 award Phase 33 criteria
Image of trial facility.

Amlitelimab

for Atopic Dermatitis (COAST 1)

This trial tests an injectable treatment called amlitelimab for people aged 12 and older with moderate to severe eczema that doesn't respond well to creams or ointments. The treatment aims to reduce skin inflammation and itching by blocking specific proteins in the immune system. The study will evaluate how effective and safe amlitelimab is.
Recruiting1 award Phase 33 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Center For Dermatology Cosmetic and Laser Surgery?
Center For Dermatology Cosmetic and Laser Surgery is a medical facility located in Fremont, California. This center is recognized for care of Atopic Dermatitis, Eczema, Psoriasis, Vitiligo, Acne and other specialties. Center For Dermatology Cosmetic and Laser Surgery is involved with conducting 16 clinical trials across 15 conditions. There are 1 research doctors associated with this hospital, such as Sunil Dhawan.